Cipla Ltd may not gain much from a UK trial showing that tocilizumab significantly reduces the risk of death when given to hospitalized patients with severe covid-19, analysts said.
Cipla is the only distributor of the drug in India under the brand Actemra through a partnership with its innovator F. Hoffmann-La Roche Ltd.“Tocilizumab is administered only in hospitals and that too to severe patients who have cytokine storms.
So, with daily new cases and severe cases falling sharply, the sales of the drug are bound to fall," Vishal Manchanda, an analyst with Nirmal Bang Institutional Equities, said.